Article

Pledge benefits retinal research

Retinal research will benefit from a multiyear financial pledge to the University of Illinois at Chicago (UIC) department of ophthalmology and visual sciences from Parent Petroleum Co., a partner with the nonprofit organization Hope for Vision.

Chicago-Retinal research will benefit from a multiyear financial pledge to the University of Illinois at Chicago (UIC) department of ophthalmology and visual sciences from Parent Petroleum Co., a partner with the nonprofit organization Hope for Vision.

“On behalf of the vision research community and patients affected with retinal degenerative conditions like retinitis pigmentosa, I would like to thank the fundraising efforts of [Parent Petroleum President] Pete Mancini and [Vice President] Mark Potaczek and the entire Parent Petroleum staff,” said Michael Grassi, MD, director of the UIC Retinal Chemical Genomics Laboratory, whose research will be supported by the commitment. “Their tireless, unwavering support over the past 15 years has helped foster discoveries that will ultimately touch the lives of millions of people.”

Dr. Grassi’s lab examines the molecular basis of common blinding retinal conditions, such as diabetic retinopathy, age-related macular degeneration, and retinitis pigmentosa. His research focuses on developing cell-based models of retinal disease and has implications for furthering the current understanding of the molecular basis of retinal disease and for providing critical insights into its treatment.

The pledge was made possible in part by Parent Petroleum’s annual golf outing, which this year raised more than $100,000 for Hope for Vision, an organization dedicated to finding a cure for blindness through scientific research.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.